Galapagos GLPG0634 Phase II study meets primary endpoint
GLPG0634 is a selective inhibitor of JAK1 (Janus kinase 1) used for treating inflammatory conditions like rheumatoid arthritis (RA). In the four week, proof-of-concept trial involving 36 RA
US-based biotechnology company Superluminal Medicines has completed a $60m Series B financing round to support its research into therapies for rare genetic forms of obesity and hypothalamic obesity.
The development of therapeutic will make use of Intrexon’s UltraVector platform and RheoSwitch Therapeutic System. Adeona will utilize Intrexon’s transgene engineering platform for the controlled, precise and continuous
Revlimid is used to treat patients with transfusion-dependent anemia due to low-or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. Patients with MDS develop severe
Amneal’s Acetonide oil line of products are generics equivalent alternatives to the Hill Dermaceuticals’ corticosteroids including DermOtic ear drops and Derma-Smoothe/FS body and scalp oils. Fluocinolone Acetonide ear